FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill

The FDA has accepted Merck's New Drug Application for its investigational once-daily, two-drug HIV pill, doravirine/islatravir (DOR/ISL), with a decision anticipated by April 28, 2026. If approved, this potential first non-integrase inhibitor-based two-drug regimen demonstrated non-inferiority to current standard three-drug therapies in pivotal Phase III studies for virologically suppressed adults. This represents a significant pipeline advancement for Merck, whose shares have underperformed year-to-date, as it seeks to establish a leading position in the competitive HIV treatment market with ongoing research and collaborations.

Analysis

Merck (MRK) has secured a key regulatory milestone with the FDA's acceptance of its New Drug Application for the investigational two-drug, single-tablet HIV regimen, doravirine/islatravir (DOR/ISL). The submission is supported by pivotal Phase III data demonstrating non-inferiority to the current standard of care, positioning DOR/ISL as a potential first-in-class non-integrase inhibitor-based two-drug therapy. However, with a PDUFA target date set for April 28, 2026, this is a long-term pipeline event rather than a near-term catalyst. This development should be viewed in the context of Merck's significant stock underperformance, having declined 15.5% year-to-date against a 0.2% rise in its industry. The company's broader HIV strategy includes additional trials for DOR/ISL and a notable collaboration with competitor Gilead Sciences (GILD) on next-generation treatments, indicating a multi-pronged approach to challenge established market leaders in a competitive therapeutic area.

Key Decisions for Investors

• Investors should view the FDA's acceptance of DOR/ISL as a positive, long-term de-risking event for Merck's pipeline, but note the distant April 2026 decision date tempers any immediate impact on valuation.
• Given the stock's 15.5% year-to-date underperformance, the current valuation may present an entry point for those with a long-term thesis on the company's HIV franchise and broader pipeline.
• It is crucial to monitor the competitive landscape, particularly developments from Gilead (GILD), as the success of its established and newly approved therapies will directly impact the market opportunity for DOR/ISL post-approval.
• Pay close attention to readouts from Merck's other islatravir combination studies, as a therapy demonstrating superiority or a more convenient dosing schedule, such as once-weekly, would be a more significant value driver than the current non-inferiority profile.